Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06565611 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
A Phase 2 study of Obesity, sponsored by Palatin Technologies.
- Active
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 4
- Study locations
NCT06565611: Active Phase 2 study of Obesity, sponsored by Palatin Technologies.
NCT06565611 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Palatin Technologies. The registered enrollment target is 108 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06565611, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Palatin Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
Primary Outcome
Percent change in patient weight from baseline (Visit 2/Day 1) to Visit 10 (Day 57) for the BMT/tirzepatide combination group compared to placebo
Conditions Studied
Interventions
- DRUG tirzepatide
- DRUG bremelanotide
Study Locations (4)
Florida
- University Clinical Research-DeLand LLC, d/b/a Accel Research - DeLand
Oklahoma
- Lynn Health Science Institute - Oklahoma City
South Carolina
- Coastal Carolina Research Center - North Charleston
Tennessee
- Lynn Institute of Chattanooga - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
What the registry record for NCT06565611 still lists
NCT06565611 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which tirzepatide is the first listed.
NCT06565611 reports a single indexed study location in Florida, Oklahoma, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06565611 about?
NCT06565611 is a clinical study titled "A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity". This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
What is the current status of trial NCT06565611?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2024-08-05. Estimated completion is 2025-03-31.
What conditions does trial NCT06565611 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06565611?
The interventions under investigation include: tirzepatide (DRUG), bremelanotide (DRUG).
Who is sponsoring clinical trial NCT06565611?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06565611 being conducted?
This trial has 4 study locations across Florida, Oklahoma, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06565611's enrollment target sits among peer trials
108 461st of 1053 higher than 592 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI